July 22, 2008 - Partnership to Accelerate Pre-Diabetes Diagnostic Development— Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced that it is collaborating with Ralph A. DeFronzo, M.D. and colleagues at The University of Texas Health Science Center at San Antonio. The partnership will help drive development of Metabolon’s pre-diabetes diagnostic products as well as provide valuable data for insulin resistance and diabetes-related research...
... Metabolon will be analyzing samples from various studies conducted by Dr. DeFronzo’s team to discover and validate biochemical biomarkers reflective of insulin resistance and beta cell dysfunction. These markers will be used to help further develop Metabolon’s diagnostic tests in the area of insulin resistance, and how this relates to risk of developing metabolic diseases such as diabetes... Metabolon's Press Releases -
Blog Archive
-
▼
2008
(233)
-
▼
July
(23)
- MicroIslet : Safety and Efficacy Data Update
- CombinatoRx : Progress in Key Programs at 2008 R&D...
- Metabolon : Collaboration with the University of T...
- Santarus and Depomed : U.S. Promotion Agreement fo...
- International Stem Cell and Novocell : Collaborati...
- XOMA 052 Phase 1 Data to be Presented At European ...
- Hollis Eden Pharmaceuticals : Phase II Clinical Tr...
- Genaera : Data on Mechanism of Inhibition of PTP-1...
- Emisphere Technologies : Data From Independent Cli...
- Animas Corporation : OneTouch Ping Glucose Manage...
- Echo Therapeutics : Clinical Study of Its Symphony...
- BodyTel : to Launch GlucoTel System in August
- Axis-Shield : AFINION HbA1c patent granted in USA
- AgaMatrix : New WaveSense Presto and Pro Glucose M...
- ARKRAY USA : National Launch of GLUCOCARD X-METER
- Georgetown University Teams with Gentag and SAIC :...
- Emisphere : License Agreement With Novo Nordisk to...
- Debiotech and STMicroelectronics : First Prototype...
- Abbott : Phase III Sub-Group Analysis Shows Invest...
- ProStrakan : Novel Testosterone Gel Significantly ...
- Isis : Robust Drug Portfolio for Diabetes and Obes...
- Sangamo BioSciences : Presentation of Phase 1b ZFP...
- HemoCue : First FDA CLIA Waiver in Diagnostics Ind...
-
▼
July
(23)